US 12,667,564

Application 17/536,892 · Granted Jun 30, 2026

Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds

Estimated expiration

March 2, 2027

100 days remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Mar 2, 2007
+ 20 years
Mar 2, 2027
PTA +0d
Mar 2, 2027
TD applied
Mar 2, 2027
Final
Mar 2, 2027

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
November 29, 2021
Earliest effective filing
March 2, 2007
Issue date
June 30, 2026
PTA
0 days
Base expiry (before PTA)
March 2, 2027

March 2, 2007 + 20 years = March 2, 2027

  • Continuation of application 16/927,497, filed Jul 13, 2020
  • Continuation of application 16/549,718, filed Aug 23, 2019
  • Continuation of application 15/710,990, filed Sep 21, 2017
  • Continuation of application 15/144,010, filed May 2, 2016
  • Continuation of application 14/504,750, filed Oct 2, 2014
  • Continuation of application 11/915,606, filed Nov 27, 2007, issued as US 8,871,779
  • National stage entry of application PCTUS2007005256, filed Mar 2, 2007
  • National stage entry of application PCTUS2007005256, filed Mar 2, 2007
  • Continuation of application 11/915,606, filed Nov 27, 2007, issued as US 8,871,779
  • National stage entry of application PCTUS2007005256, filed Mar 2, 2007
  • Continuation of application 14/504,750, filed Oct 2, 2014
  • Continuation of application 11/915,606, filed Nov 27, 2007, issued as US 8,871,779
  • National stage entry of application PCTUS2007005256, filed Mar 2, 2007
  • Continuation of application 15/144,010, filed May 2, 2016
  • Continuation of application 14/504,750, filed Oct 2, 2014
  • Continuation of application 11/915,606, filed Nov 27, 2007, issued as US 8,871,779
  • National stage entry of application PCTUS2007005256, filed Mar 2, 2007
  • Continuation of application 15/710,990, filed Sep 21, 2017
  • Continuation of application 15/144,010, filed May 2, 2016
  • Continuation of application 14/504,750, filed Oct 2, 2014
  • Continuation of application 11/915,606, filed Nov 27, 2007, issued as US 8,871,779
  • National stage entry of application PCTUS2007005256, filed Mar 2, 2007
  • Continuation of application 16/549,718, filed Aug 23, 2019
  • Continuation of application 15/710,990, filed Sep 21, 2017
  • Continuation of application 15/144,010, filed May 2, 2016
  • Continuation of application 14/504,750, filed Oct 2, 2014
  • Continuation of application 11/915,606, filed Nov 27, 2007, issued as US 8,871,779
  • National stage entry of application PCTUS2007005256, filed Mar 2, 2007
  • PRO60/778,258 — Provisional — not used for base term
  • PRO60/778,258 — Provisional — not used for base term
  • PRO60/778,258 — Provisional — not used for base term
  • PRO60/778,258 — Provisional — not used for base term
  • PRO60/778,258 — Provisional — not used for base term
  • PRO60/778,258 — Provisional — not used for base term
  • PRO60/778,258 — Provisional — not used for base term
  • PRO60/778,258 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to March 2, 2027

  • US 8,748,611· Application 13/294,546Capping patent

    Processes for preparing morphinan-6-one products with low levels of alpha beta-unsaturated compounds

    Filing date
    Nov 11, 2011
    Earliest effective filing
    Mar 2, 2007
    Issue date
    Jun 10, 2014
    PTA
    +213 days
    Calculated expiration
    Oct 1, 2027

    Continuation of 11/915,606, filed Nov 27, 2007, issued as US 8,871,779

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    Mar 2, 2007 + 20y + 213d PTA = Oct 1, 2027

  • US 12,667,564· Application 17/536,892(from application 17/536,892)Capping patent

    Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds

    Filing date
    Nov 29, 2021
    Earliest effective filing
    Mar 2, 2007
    Issue date
    Jun 30, 2026
    PTA
    0 days
    Calculated expiration
    Mar 2, 2027

    Continuation of 16/927,497, filed Jul 13, 2020

    Continuation of 16/549,718, filed Aug 23, 2019

    Continuation of 15/710,990, filed Sep 21, 2017

    Continuation of 15/144,010, filed May 2, 2016

    Continuation of 14/504,750, filed Oct 2, 2014

    Continuation of 11/915,606, filed Nov 27, 2007, issued as US 8,871,779

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    Continuation of 11/915,606, filed Nov 27, 2007, issued as US 8,871,779

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    Continuation of 14/504,750, filed Oct 2, 2014

    Continuation of 11/915,606, filed Nov 27, 2007, issued as US 8,871,779

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    Continuation of 15/144,010, filed May 2, 2016

    Continuation of 14/504,750, filed Oct 2, 2014

    Continuation of 11/915,606, filed Nov 27, 2007, issued as US 8,871,779

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    Continuation of 15/710,990, filed Sep 21, 2017

    Continuation of 15/144,010, filed May 2, 2016

    Continuation of 14/504,750, filed Oct 2, 2014

    Continuation of 11/915,606, filed Nov 27, 2007, issued as US 8,871,779

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    Continuation of 16/549,718, filed Aug 23, 2019

    Continuation of 15/710,990, filed Sep 21, 2017

    Continuation of 15/144,010, filed May 2, 2016

    Continuation of 14/504,750, filed Oct 2, 2014

    Continuation of 11/915,606, filed Nov 27, 2007, issued as US 8,871,779

    National stage entry of PCTUS2007005256, filed Mar 2, 2007

    Mar 2, 2007 + 20y = Mar 2, 2027

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/536,892 · US 12,667,564

PatentReply compiles the prosecution history behind US 12,667,564: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12667564

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.